These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Sevelamer: where are the data? McCarron DA Kidney Int; 2003 Dec; 64(6):2329; author reply 2329-30. PubMed ID: 14633168 [No Abstract] [Full Text] [Related]
3. [Front line of management of hyperphosphatemia in hemodialysis patients]. Yumita S Clin Calcium; 2004 May; 14(5):771-7. PubMed ID: 15577041 [TBL] [Abstract][Full Text] [Related]
4. Evaluation of morbidity and mortality data related to cardiovascular calcification from calcium-containing phosphate binder use in patients undergoing hemodialysis. Mason MA; Shepler BM Pharmacotherapy; 2010 Jul; 30(7):741-8. PubMed ID: 20575637 [TBL] [Abstract][Full Text] [Related]
5. [Treatment of hyperphosphatemia with sevelamer hydrochloride in CKD patients: effects on vascular calcification and mortality]. Koizumi M; Fukagawa M Clin Calcium; 2010 Nov; 20(11):1700-8. PubMed ID: 21037391 [TBL] [Abstract][Full Text] [Related]
6. Two year comparison of sevelamer and calcium carbonate effects on cardiovascular calcification and bone density. Asmus HG; Braun J; Krause R; Brunkhorst R; Holzer H; Schulz W; Neumayer HH; Raggi P; Bommer J Nephrol Dial Transplant; 2005 Aug; 20(8):1653-61. PubMed ID: 15930018 [TBL] [Abstract][Full Text] [Related]
7. Vascular calcification in patients with end-stage renal disease. Floege J; Ketteler M Nephrol Dial Transplant; 2004 Aug; 19 Suppl 5():V59-66. PubMed ID: 15284362 [TBL] [Abstract][Full Text] [Related]
8. [Pharmacological and clinical trial data on a novel phosphate-binding polymer (sevelamer hydrochloride), a medicine for hyperphosphatemia in hemodialysis patients]. Nagano N; Fukushima N Nihon Yakurigaku Zasshi; 2003 Nov; 122(5):443-53. PubMed ID: 14569164 [TBL] [Abstract][Full Text] [Related]
10. [Mechanism and therapy of vascular calcification]. Hara S; Yokoyama K Clin Calcium; 2004 May; 14(5):752-5. PubMed ID: 15577037 [TBL] [Abstract][Full Text] [Related]
11. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis. Brandi L Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159 [TBL] [Abstract][Full Text] [Related]
12. Different routes bridging calcium in Japanese hemodialysis patients. Hamano T; Fujii N; Ito T; Imai E Ther Apher Dial; 2005 Feb; 9(1):32-8. PubMed ID: 15828903 [TBL] [Abstract][Full Text] [Related]
13. Health and economic consequences of sevelamer use for hyperphosphatemia in patients on hemodialysis. Huybrechts KF; Caro JJ; Wilson DA; O'Brien JA Value Health; 2005; 8(5):549-61. PubMed ID: 16176493 [TBL] [Abstract][Full Text] [Related]